By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia said today that it has hired Ferrer inCode to distribute its MammaPrint breast cancer diagnostic test in Latin America.

The MammaPrint test is used to identify patients who are at high risk of early metastasis and who are likely to develop metastases within five years after surgery.

Ferrer inCode is a subsidiary of Spain's Grupo Ferrer Internacional that is focused on personalized medicine, genomics, proteomics, and other related technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.